KRAS and neoplasm: Notably, both WT‐KRAS (G12D) mice and Med23−/−‐KRAS (G12D) mice receiving CD103+ T cells exhibited a significant decrease in tumor number compared with the mice that received CD103− T cells (Figure 6E,F).